Ignite Creation Date:
2024-05-06 @ 12:08 AM
Last Modification Date:
2024-10-26 @ 10:45 AM
Study NCT ID:
NCT01506258
Status:
UNKNOWN
Last Update Posted:
2012-01-19
First Post:
2012-01-05
Brief Title:
Autologous Stem Cells in Newborns With Oxygen Deprivation
Sponsor:
Hospital Universitario Dr Jose E Gonzalez
Organization:
Hospital Universitario Dr Jose E Gonzalez
Study Overview
Official Title:
Effects of the Infusion of Autologous Non-cryopreserved CD34 Cells in Newborns With Asphyxia
Status:
UNKNOWN
Status Verified Date:
2012-01
Last Known Status:
RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to determine whether the plasticity of autologous intravenous application of cord blood stem cells would improve the clinical course of asphyxiated newborns
Detailed Description:
When there is oxygen deprivation more frequently in premature newborns the brain and other organs suffer severe consequences There is evidence that hematopoietic stem cells can help in this scenario by promoting the release of growth-enhancing factors that can help control the damage due to their homing capacity which attracts them to injured sites
Cord and placental blood have a high concentration of these stem cells and because its obtention is relatively easy it seems like a feasible treatment in perinatal hypoxia
There are current clinical trials that use cryopreserved cord blood for these patients but to do that the stem cells have to be frozen and then thawed to be infused losing a considerable amount of stem cells almost half of them We want to evaluate the same condition but infusing non-cryopreserved autologous cord and placental blood because we believe it can be more beneficial due to the greater amount of cells infused the avoidance of the cryoprotection agents toxicity and the lower costs
Cord and placental blood have a high concentration of these stem cells and because its obtention is relatively easy it seems like a feasible treatment in perinatal hypoxia
There are current clinical trials that use cryopreserved cord blood for these patients but to do that the stem cells have to be frozen and then thawed to be infused losing a considerable amount of stem cells almost half of them We want to evaluate the same condition but infusing non-cryopreserved autologous cord and placental blood because we believe it can be more beneficial due to the greater amount of cells infused the avoidance of the cryoprotection agents toxicity and the lower costs
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None